Increasing evidence from preclinical and early clinical studies suggests that flavonoids can modulate several key pathological mechanisms of AD, including oxidative stress, neuroinflammation, Aβ accumulation, and tau pathology. The gene discussed is MAPT; the disease is Alzheimer disease.